Repatha® is a human monoclonal IgG2 directed against human PCSK9. Repatha® binds to PCSK9 and inhibits circulating PCSK9 from binding to the low density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha® increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.1

Repatha® Mechanism of Action

Repatha® mechanism of action video: 1 of 3

What is PCSK9?

PCSK9 is a protein that promotes degradation of LDLRs. This results in fewer LDLRs on the liver cell surface, increasing plasma LDL-C levels2

Repatha® mechanism of action video: 2 of 3

Why Repatha® inhibits PCSK9

By inhibiting the binding of PCSK9 to LDLR, Repatha® permits LDLRs to recycle back to the liver cell surface1

This in turn increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels1

Repatha® mechanism of action video:3 of 3

How Repatha® lowers LDL-C levels

Repatha® lowers LDL-C levels by inhibiting PCSK9, increasing the number of LDLRs on the hepatocyte surface, thereby resulting in lower LDL-C plasma concentrations1

PCSK9 Inhibition With Repatha®

Plasma LDL-C levels decrease
LDLR surface expression increase
PCSK9 levels decrease